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The bisphosphonate study is a collaborative effort between the NASA and JAXA space agencies to investigate the 
potential for antiresorptive drugs to mitigate bone changes associated with long-duration spaceflight. Elevated bone 
resorption is a hallmark of human spaceflight and bed rest (common zero-G analog). We tested whether an 
antiresorptive drug in combination with in-flight exercise would ameliorate bone loss and hypercalcuria during long-
duration spaceflight. Measurements include DXA, QCT, pQCT, and urine and blood biomarkers. We have 
completed analysis of 7 crewmembers treated with alendronate during flight and the immediate postflight (R+<2 
week) data collection in 5 of 10 controls without treatment. Both groups used the advanced resistive exercise device 
(ARED) during their missions.  
We previously reported the pre/postflight results of crew taking alendronate during flight (Osteoporosis Int. 
24:2105–2114, 2013). The purpose of this report is to present the 12-month follow-up data in the treated astronauts 
and to compare these results with preliminary data from untreated crewmembers exercising with ARED (ARED 
control) or without ARED (Pre-ARED control). Results: the table presents DXA and QCT BMD expressed as 
percentage change from preflight in the control astronauts (18 Pre-ARED and the current 5 ARED-1-year data not 
yet available) and the 7 treated subjects. As shown previously the combination of exercise plus antiresorptive is 
effective in preventing bone loss during flight. Bone measures for treated subjects, 1 year after return from space 
remain at or near baseline values. Except in one region, the treated group maintained or gained bone 1 year after 
flight. Biomarker data are not currently available for either control group and therefore not presented. However, data 
from other studies with or without ARED show elevated bone resorption and urinary Ca excretion while 
bisphosphonate treated subjects show decreases during flight. Comparing the two control groups suggests significant 
but incomplete improvement in maintaining BMD using the newer exercise protocols compared to earlier resistive 
exercise protocols. Quantitative characterization of this improvement requires additional measurements in the 
ARED control group that we are currently collecting. In conclusion, these results indicate that an antiresorptive may 
be an effective adjunct to exercise during long-duration spaceflight. 
 
% Change from Preflight (Mean ± SD) 
 
 Pre-ARED Control 
(n=18) 
ARED Control 
(n=5) 
Alendronate Treated 
(n=7) 
 R+<2 week R+<2 week R+<2 week R+1 year 
DXA BMD     
Total Hip -6.2 ± 2.8 -2.7 ± 3.2 -0.2 ± 1.5 0.8 ± 1.4 
Trochanter -6.8 ± 4.8 -3.8 ± 2.9 0.02 ± 2.3 2.1 ± 1.2 
Femur Neck -6.6 ± 3.0 0.8 ± 4.6 -0.7 ± 1.2  1.5 ± 1.7  
Lumbar Spine -3.9 ± 3.2 -3.7 ± 2.3 2.8 ± 4.0 3.9 ± 3.8 
QCT BMD     
Trabecular Total Hip  −13.6 ± 6.4 -6.9 ± 8.0 -1.1 ± 9.8 -1.1 ± 12.1 
Cortical Total Hip  −3.2 ± 3.5 -3.6 ± 0.4 -0.6 ± 4.7 -2.9 ± 3.7 
Trabecular Trochanter −13.5 ± 6.5 -5.6 ± 7.8 -1.9 ± 9.9 -1.2 ± 12.4 
Cortical Trochanter −3.2 ± 3.3 -4.6 ± 1.4 -0.5 ± 5.0 -3.2 ± 4.3 
Trabecular Femur Neck −15.0 ± 9.8 -15.8 ± 15.8 6.5 ± 14.8 2.8 ± 7.2 
Cortical Femur Neck −4.0 ± 5.5 -3.2 ± 2.6 -1.0 ± 4.8 -3.9 ± 3.1 
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